EGFR and adenocarcinoma: Notably, we revived the growth of two adenocarcinomas—PDX#18 (with low agrin–YAP and no evidence of EGFR mutation) and PDX#20 (high agrin, moderate EGFR with del19 mutation, and high YAP) in SCID mice used for validating the efficacy of osimertinib–VT107 combinations (Figure 7D; Figure S10H, Supporting Information).